Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enlituo Plus FOLFOX vs Erbitux Plus FOLFOX in First-line Advanced Colorectal Cancer
NCT07595276Phase 3Recruiting
- Sponsor
- Taizhou Mabtech Pharmaceutical
- Start
- May 2026
- Primary completion
- Oct 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of cetuximab in colorectal cancer (CRC), sponsored by Taizhou Mabtech Pharmaceutical. Started May 2026; status: recruiting.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07595276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07595276.